{"id":34830,"date":"2018-02-20T08:30:17","date_gmt":"2018-02-20T07:30:17","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=34830"},"modified":"2018-02-20T12:38:49","modified_gmt":"2018-02-20T11:38:49","slug":"principi-attivi-primato-italiano-difendere","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/principi-attivi-primato-italiano-difendere\/","title":{"rendered":"Active ingredients Italian primacy to be defended"},"content":{"rendered":"<div class=\"page\" title=\"Page 1\">\n<div class=\"section\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<h3>All the numbers of a 3.6 billion euro sector<\/h3>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The active pharmaceutical ingredients industry is confirmed as an Italian manufacturing sector of excellence: this is what emerges from the Aschimfarma 2018 Forum &#039;Research and technology: the new frontiers for pharmaceutical chemistry&#039; in Milan.<\/p>\n<p>With a share of 9% on total world production, pharmaceutical raw materials have been challenging competition from Asian and North American giants for years, with an export share of 85% (40% in the USA, 36% in Europe, 18% in Japan) and a turnover of 3.6 billion euros.<\/p>\n<p>The sector, represented in Italy by Aschimfarma \u2013 the Federchimica Association which represents producers in Italy \u2013 allocates 3% of its turnover to research, above all applied to development, mainly for process optimization.<\/p>\n<p>It can be estimated that the sector represents 10% of the research and development expenditure of the total chemical industry (including pharmaceuticals). \u201cOur sector&#039;s attention to research, combined with high levels of product quality, safety and respect for the environment, have proved to be winning factors over Asian competition, which has led multinational pharmaceutical companies to return to collaborating on projects of development with Italian companies\u201d, said Gian Mario Baccalini, president of Aschimfarma.<\/p>\n<p>&quot;The important thing for companies - added Baccalini - is now to defend this leadership position, based on quality, integrating it with elements that allow it to be consolidated&quot;.<\/p>\n<\/div>\n<div class=\"column\">\n<p>Margherita Lopes \u2013 PharmaKronos \u2013 20 February 2018<\/p>\n<p>Related news:\u00a0<a href=\"https:\/\/aschimfarma.federchimica.it\/Stampa\/dettaglio-evento\/2018\/02\/19\/default-calendar\/ricerca-e-tecnologia-le-nuove-frontiere-per-la-chimica-farmaceutica\" target=\"_blank\" rel=\"noopener\">Research and technology: the new frontiers<\/a><\/p>\n<div class=\"sf_eventBasicInfo\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Tutti i numeri di un settore da 3,6 mld euro L&#8217;industria dei principi attivi farmaceutici si conferma un settore manifatturiero italiano d&#8217;eccellenza: \u00e8 quanto emerge del Forum Aschimfarma 2018 &#8216;Ricerca e tecnologia: le nuove frontiere per la chimica farmaceutica&#8217; a Milano. Con una quota del 9% sul totale della produzione mondiale, le materie prime farmaceutiche &hellip;<\/p>","protected":false},"author":4,"featured_media":9147,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[31,29],"class_list":["post-34830","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-generici","tag-prezzo-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=34830"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34830\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9147"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=34830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=34830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=34830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}